GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 34 Key Financial Ratios Year ended 31-Mar-22 31-Mar-21 Efficiency Ratios Current Ratio Current assets # / current liabilities 2.19 1.51 Inventory turnover ratio Sale of products / Average inventories 6.73 6.28 Debtors turnover ratio Sale of products / Average trade receivables 16.58 20.04 Ratios are calculated including profits from discontinued operations but excludes the impact of sale of brands and identified assets and other exceptional items (Refer Note 40 and 55 of the Standalone Financial Statements). *Net profit margin (%) excluding the impact of tax adjustment of prior years would be 17.19%, Return on Net Worth would be 28.69%. # Current Assets includes cash and bank balance which is mainly on account of cash received from sale of brands. 6. Regulatory affairs The following applications were submitted to Central Drugs Standard Control Organisation (CDSCO) for marketing authorisation in India: • Adsorbed Diphtheria, Tetanus, Pertussis (Acellular Component) and Inactivated Poliomyelitis vaccine I.P. (Infanrix-IPV) for active immunisation in infants from the age of two months against diphtheria, tetanus, pertussis and poliomyelitis, as well as a booster dose for children who have previously been immunised with diphtheria, tetanus, pertussis (DTP) and polio antigens • Label expansion of Mepolizumab Solution for Injection (Nucala) to include two additional indications viz. Eosinophilic granulomatosis with polyangiitis (EGPA) and Hypereosinophilic syndrome (HES) in adults • Marketing authorisation was successfully obtained for Herpes Zoster (Shingrix) vaccine for prevention of Herpes Zoster (HZ) and Post- Herpetic Neuralgia (PHN), in adults 50 years of age or older, along with an alternate ready-to-use liquid formulation of Rotavirus vaccine (Rotarix liquid) We also applied to CDSCO for two Global Clinical Trial Applications to conduct a multi-country phase 2 study with Belantamab Mafodotin, in participants with Relapsed or Refractory Multiple Myeloma, along with a Phase 1/Phase 2 study with Staphylococcus aureus vaccine, for prevention of staphylococcal infections respectively. The following Clinical Trial Applications were also approved during the year: • A Global Clinical Trial Application for conducting a multi-country phase 3 study with Respiratory Syncytial Virus (RSV) Maternal (RSVPreF3) vaccine in India [Study RSV-MAT-012] • A local Phase 3 Clinical Trial Application for Herpes Zoster Vaccine (Shingrix) [Study Zoster-081] • A real-world evidence, post marketing observational non-interventional study with Mepolizumab Injection in Emerging Markets [Nucala Effectiveness Study (NEST)] These filings and approvals will enable timely access to new and innovative therapeutic options and vaccines for patients in India, besides improving compliance and convenience of use with new formulations. 7. Medical affairs and medical governance During the year, we launched several innovative digital programmes targeted at changing the ways in which we connect with our HCPs and key external experts. The GSK Anti-infectives medical team has been at the forefront of driving correct science through local, regional, and national meetings, and prestigious congress presentations, as well as participating in industry-wide stakeholder consultations on combating antimicrobial resistance (AMR). The Primary Care medical team delivered over 200 scientific presentations to over 30,000 HCPs and conducted more than 300 one-on-one interactions with experts, including ear, nose and throat specialists (ENTs). At GSK, we are advancing science through Phase 4 clinical trials that generate evidence on the safety and efficacy of our drugs in patients, along with several successful publications driving strong scientific messages on the appropriate use of antibiotics and reducing AMR. In 2022, our Medical Affairs team has been leading ‘ASCENT’, a programme on ‘Advanced Surgical Conclave for ENTs’ for disseminating high science to ENTs on advancements in surgery and perioperative infection management. Through more than 900 scientific presentations to over 30,000 HCPs and approximately 1,500 one- on-one scientific interactions with dermatologists, the Dermatology medical team continued its efforts to drive scientific discussions on appropriate use of Directors’ Report